IRIS
PERA, MARIA CARMELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.200
NA - Nord America 1.971
EU - Europa 1.071
SA - Sud America 741
AF - Africa 195
Continente sconosciuto - Info sul continente non disponibili 129
OC - Oceania 2
Totale 7.309
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.867
SG - Singapore 1.358
BR - Brasile 550
VN - Vietnam 488
CN - Cina 436
IT - Italia 383
BD - Bangladesh 354
HK - Hong Kong 277
NL - Olanda 218
FR - Francia 158
ZA - Sudafrica 133
AR - Argentina 74
RU - Federazione Russa 59
DE - Germania 54
IN - India 50
IQ - Iraq 41
AT - Austria 37
GB - Regno Unito 37
IE - Irlanda 35
CO - Colombia 33
MX - Messico 32
CA - Canada 31
EC - Ecuador 24
TR - Turchia 23
PK - Pakistan 22
MA - Marocco 20
JP - Giappone 18
VE - Venezuela 16
PH - Filippine 15
PY - Paraguay 15
ID - Indonesia 14
SA - Arabia Saudita 14
PL - Polonia 13
UA - Ucraina 12
UY - Uruguay 11
UZ - Uzbekistan 11
JO - Giordania 10
KE - Kenya 10
KR - Corea 10
TN - Tunisia 10
CL - Cile 9
ES - Italia 9
JM - Giamaica 9
LT - Lituania 9
SE - Svezia 9
DZ - Algeria 7
HN - Honduras 7
AZ - Azerbaigian 6
BG - Bulgaria 6
IL - Israele 6
PE - Perù 6
TH - Thailandia 6
DO - Repubblica Dominicana 5
EG - Egitto 5
NP - Nepal 5
TT - Trinidad e Tobago 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
KZ - Kazakistan 4
LB - Libano 4
CH - Svizzera 3
CR - Costa Rica 3
ET - Etiopia 3
GE - Georgia 3
GT - Guatemala 3
IR - Iran 3
MY - Malesia 3
PT - Portogallo 3
RO - Romania 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BE - Belgio 2
CI - Costa d'Avorio 2
EE - Estonia 2
FI - Finlandia 2
GR - Grecia 2
GY - Guiana 2
KG - Kirghizistan 2
LK - Sri Lanka 2
LV - Lettonia 2
MD - Moldavia 2
NG - Nigeria 2
NI - Nicaragua 2
OM - Oman 2
RS - Serbia 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
AO - Angola 1
BH - Bahrain 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BZ - Belize 1
CM - Camerun 1
HU - Ungheria 1
KW - Kuwait 1
LC - Santa Lucia 1
NO - Norvegia 1
PA - Panama 1
Totale 7.175
Salva come PNG Salva come JPEG
Città #
Singapore 606
San Jose 512
Council Bluffs 262
Hong Kong 261
Ashburn 165
Beijing 161
Ho Chi Minh City 151
Santa Clara 137
Dallas 128
Hanoi 125
Johannesburg 120
Groningen 103
Lauterbourg 96
Los Angeles 57
Milan 57
New York 49
Boardman 45
São Paulo 43
Buffalo 42
Moscow 36
Dublin 34
Rio de Janeiro 34
Rome 27
Nuremberg 25
Haiphong 21
Bologna 19
Munich 17
Parma 16
Shanghai 16
Naples 15
Brasília 14
Da Nang 14
Hefei 14
Chicago 13
Tokyo 13
Vienna 13
Baghdad 12
Biên Hòa 11
Quito 11
Amman 10
San Francisco 10
Ankara 9
Brooklyn 9
Can Tho 9
Columbus 9
Frankfurt am Main 9
Nairobi 9
Ninh Bình 9
Tashkent 9
Toronto 9
Turin 9
Atlanta 8
Dhaka 8
Guangzhou 8
Hải Dương 8
London 8
Warsaw 8
Boston 7
Caracas 7
Curitiba 7
Denver 7
Houston 7
New Delhi 7
Phoenix 7
Tianjin 7
Baku 6
Belo Horizonte 6
Bogotá 6
Catania 6
Figino 6
Kingston 6
Montevideo 6
Seattle 6
Thái Nguyên 6
Amsterdam 5
Aracaju 5
Asunción 5
Brescia 5
Buenos Aires 5
Carpi 5
Casablanca 5
Erbil 5
Forlì 5
Guarulhos 5
Hyderabad 5
Istanbul 5
Jeddah 5
Karachi 5
Karbala 5
Mexico City 5
Montreal 5
Recife 5
Rosario 5
Stockholm 5
Bắc Ninh 4
Campinas 4
Caxias do Sul 4
Charlotte 4
Conselheiro Lafaiete 4
Dammam 4
Totale 3.887
Salva come PNG Salva come JPEG
Nome #
Airway Colonization in Children with Medical Complexity: Challenges and Management Strategies 161
Beyond Muscle Weakness: Unraveling Endocrine and Metabolic Dysfunctions in Duchenne Muscular Dystrophy, a Narrative Review 136
Myostatin Modulation in Spinal Muscular Atrophy: A Systematic Review of Preclinical and Clinical Evidence 113
An observational study of functional abilities in infants, children, and adults with type 1 SMA 97
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 93
Myostatin Levels in SMA Following Disease-Modifying Treatments: A Multi-Center Study 93
Scoliosis in spinal muscular atrophy in the era of disease-modifying therapy: a scoping review 93
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 92
What did we learn from new treatments in SMA? A narrative review 88
Risdiplam in Type 1 Spinal Muscular Atrophy 88
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA 86
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression 86
Longitudinal Assessment of 4‐Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen 82
Two journeys, one diagnosis: exploring the clinical outcomes of twins with congenital myopathy 82
Spinal muscular atrophy — insights and challenges in the treatment era 81
Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study 81
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 78
An observational study of functional abilities in infants, children, and adults with type 1 SMA 77
Caregivers’ Expectations on Possible Functional Changes following Disease-Modifying Treatment in Type II and III Spinal Muscular Atrophy: A Comparative Study 77
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 76
Patients on treatment with risdiplam in Italy: challenges in the interpretation of the real-world data 76
Early neurodevelopmental assessment in Duchenne muscular dystrophy 76
Clinical Phenotype of Pediatric and Adult Patients With Spinal Muscular Atrophy With Four SMN2 Copies: Are They Really All Stable? 75
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 74
Pregnancy in the Era of Disease-Modifying Therapies for Spinal Muscular Atrophy: Considerations From a Case Report 74
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 73
Clinical Variability in Spinal Muscular Atrophy Type III 73
Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis 72
Design and Usability Testing of a Novel Internet-Delivered Cognitive Behavioral Therapy (iCBT) Software Platform for Children with Anxiety 72
1st Italian SMA Family Association Consensus Meeting: Management and recommendations for respiratory involvement in spinal muscular atrophy (SMA) types I-III, Rome, Italy, 30-31 January 2015 71
Assessing floppy infants: a new module 70
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 70
Prevalence of Duchenne muscular dystrophy in Italy: a nationwide survey 69
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 68
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 68
Developmental milestones in type I spinal muscular atrophy 68
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 68
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 67
Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study 67
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 67
Traumatic Childbirth Experiences and their Association with Postpartum Psychiatric Disorders: A Systematic Review 67
Longitudinal natural history of type I spinal muscular atrophy: A critical review 66
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 65
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 64
Sleep disorders in spinal muscular atrophy 64
High Expression of SMN circ4-2b-3 in SMA I Children Treated with Nusinersen is Associated with Improved Motor Outcomes 64
Italian validation of the SMA independence scale–upper limb module 64
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module 64
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 63
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 63
Old measures and new scores in spinal muscular atrophy patients 63
Age and baseline values predict 12 and 24-month functional changes in type 2 SMA 63
Early treatment of type II SMA slows rate of progression of scoliosis 63
Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions 62
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 62
Long-term natural history in type II and III spinal muscular atrophy: a 4-year international study on the Hammersmith Functional Motor Scale Expanded 62
Developmental milestones in type I spinal muscular atrophy 62
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 61
Revised upper limb module for spinal muscular atrophy: Development of a new module 60
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 60
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 59
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 59
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 59
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 59
Development of an academic disease registry for spinal muscular atrophy 58
Profile of cognitive abilities in spinal muscular atrophy type II and III: what is the role of motor impairment? 58
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy 58
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 58
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 58
Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis 58
Long-term evolution of neuropsychological competences in encephalopathy with status epilepticus during sleep: a variable prognosis 57
Neonatal hypotonia and neuromuscular conditions 57
Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study 57
Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study 57
Long term follow-up of scoliosis progression in type II SMA patients 57
How to Manage Electrical Status Epilepticus in Sleep 56
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 56
Predominant distal muscle involvement in spinal muscular atrophy 55
Revised upper limb module for spinal muscular atrophy: 12 month changes 55
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 55
Paediatric optic neuritis: factors leading to unfavourable outcome and relapses 54
Neurodevelopmental and mental disorders in children with type I and presymptomatic spinal muscular atrophy 54
Gain and loss of abilities in type II SMA: A 12-month natural history study 53
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 53
Posterior brain damage and cognitive impairment in pediatric multiple sclerosis 53
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 52
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy 52
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 52
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 51
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 51
Revised upper limb module for spinal muscular atrophy: Development of a new module 50
Therapy of encephalopathy with status epilepticus during sleep (ESES/CSWS syndrome): an update 50
SFP CO-31 - Inflammatory optic neuritis: Course and prognostic factors in 102 children|SFP CO-31 - Névrites optiques inflammatoires: évolution et facteurs pronostiques chez 102 enfants 50
Treatment of spinal muscular atrophy 50
The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage 49
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 48
Epileptic Encephalopathies with Status Epilepticus during Sleep: New Techniques for Understanding Pathophysiology and Therapeutic Options 48
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 48
Intravenous methylprednisolone pulse therapy for children with epileptic encephalopathy 48
Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019 48
Totale 6.700
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.163
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.163
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20251.631 0 0 318 55 85 97 50 55 234 215 111 411
2025/20265.193 325 491 635 479 585 202 552 120 564 451 470 319
2026/2027485 263 222 0 0 0 0 0 0 0 0 0 0
Totale 7.309